Microsomal cytochrome P450 monooxygenases of the groups 1 -3 are mainly 
Introduction:
Mammalian cytochrome P450 monooxygenases (CYP; E.C. 1.14.14.1 ) are ubiquitous proteins: on the one hand they are involved in the oxidation of several endogenous compounds such as steroids, prostaglandins and fatty acids; on the other hand CYPs of the groups 1, 2 and 3 play a key role in the metabolism of xenobiotics which consists of two phases: in phase 1 called functionalization CYPs are responsible for the addition of functional groups to foreign compounds by hydroxylation, dealkylation, deamination etc.. In phase 2 known as conjugation transferases use those groups to couple charged molecules or groups making the modified compound more water soluble which allows its efficient excretion.
Although the CYPs are expressed at different levels in many tissues, liver contains 90 % of those CYPs relevant for detoxification. In contrast to procaryotic CYPs the respective eucaryotic proteins are membrane bound and are mainly found on the cytosolic side of the endoplasmatic reticulum. The activity of the CYPs depends strongly on the electron transfer from NADPH to the heme group of the CYPs by accessory proteins like NADPH cytochrome P450 reductase (CPR; EC 1.6.2.4) and cytochrome b5 (Cyb5).
Characteristic for those microsomal CYPs are broad substrate specificities with individually different phenotypes due to polymorphisms, duplications and different expression levels. Thus, they play a crucial role in drug interactions and are therefore highly important to the pharmaceutical industry. Within the last 15 years in vivo experiments using animal models have been replaced by in vitro studies using human enzymes from different sources. [1] [2] [3] [4] [5] [6] Microsomal preparations or cellular systems such as liver slices and human hepatocytes are used and provide the advantage of a maintained cellular integrity concerning other enzymes, cofactors, transporters etc., contributing to the activity as well. Whereas all those systems contain a complete set of enzymes, recombinant expression systems allow the production of single enzymes for specific applications such as drug metabolism. In contrast to the human sources the availability of recombinant enzymes is not limited.
Currently several recombinant expression systems are under investigation:
mammalian systems which provide transient (COS, HepG2) and permanent (V79) expression of individual human CYPs are complicated and expensive to handle and often exhibit low levels of functional enzyme. [4, 7, 8] Anyway, some of them are commercially available. Among the simpler systems mainly baculovirus infected insect cells are currently used to purify microsomes containing individual mammalian CYPs and accessory proteins (CPR & Cyb5) at reasonable levels. [9] Drawbacks of the insect cell based systems are the complicated cultivation of the insect cells and the expensive media containing heme or heme precursors making the scale-up difficult. Due to the cheap cultivation procedures and media required and the ease of handling, E. coli was used as host for the expression of a couple of CYPs as well. [10] [11] [12] However, a truncation or at least modification of the N-terminal membrane anchor sequence was required. [13] For the expression of some but not all CYPs in E. coli the addition of heme or its precursors is needed. The yeast S. cerevisae combines the ease of handling of prokaryotic systems with the features of eukaryotic systems such as posttranslational processing. Whereas initial experiments did not provide reasonable cytochrome P450 expression levels, the group of Pompon was able to improve the S. cerevisiae system substantially by coexpression of Cyb5, CPR, [14, 15] and later also potentially required phase 2 enzymes such as epoxide hydrolase. [5, 16] Meanwhile a couple of mammalian microsomal CYPs have been expressed in S.
cerevisiae. [17] [18] [19] Also some unconventional yeasts such as Schizosaccharomyces pombe or Yarrowia lipolytica have been used for the expression of human cytochromes P450. [20, 21] Due to the high expression yields of soluble proteins obtained by intracellular as well as secreted expression and the ease of handling, the methylotrophic yeast Pichia pastoris has gained in popularity as expression system during the last few years. A couple of proteins have been expressed in very high yields (up to 10 g l -1 ). [22, 23] Despite additional advantages of Pichia over the common baker's yeast such as a glycosilation pattern which is closer to humans than that of S. cerevisiae, only three eukaryotic CYPs from spiny dogfish shark, spiny lobster and cassava have been expressed so far; [24] [25] [26] none of them is of human origin.
Here we present the establishment of Pichia pastoris as expression system for the production and characterization of human microsomal CYPs. CYP2D6, the model enzyme we have chosen is a polymorphically expressed microsomal cytochrome P450, [27] which almost exclusively catalyses the conversion of more than 50 relevant drugs including cardivacular drugs, β-adrenergic blocking agents, tricyclic antidepressants and opioid derivatives. [28, 29] Overall at least 72 different CYP2D6 alleles exist: splice-variants, frame-shift mutations, deletions and premature stop codons result in a complete defect of the enzyme. 5-10 % of the caucasian population carry this phenotype. [30] Others genotypes show significant phenotype alterations due to shifted kinetic properties or varied expression levels. [31] Poor metabolizers for example lacking CYP2D6 activity and thus do not have an alternative pathway for the detoxification of respective substrates. In order to allow the analysis of the relevant CYPs and their variants separately a simple and fast recombinant expression system is needed.
Results

Cloning and Expression of CYP2D6 and CPR
The genes encoding CYP2D6 and CPR were cloned and ligated separately each into the vector pPICZ A under control of the AOX1 promotor as described in the methods Human liver microsomes as well as commercially available E. coli membrane fractions containing truncated CYP2D6 variants and human oxidoreductase served as positive controls and showed activity using both assays (data not shown).
Due to the fact that mixtures of microsomes containing properly folded CYP2D6 (as confirmed by CO-difference spectrum, data not shown) and microsomes containing active CPR did not yield any CYP activity, the limiting factor seemed to be the electron transfer.
Coexpression of CYP2D6 and CPR
In order to improve the electron transfer system clones coexpressing human CPR and CYP2D6 were generated: the complete expression cassettes of both enzymeseach including promoter and terminator -were combined within one vector using a cloning strategy which was recently used for the coexpression of heavy and light chain to produce functional active Fab fragments. [32] After transformation of the resulting vector pPICZ-CPR-CYP2D6 into P. pastoris X33, the chromosomal integration of both expression cassettes was confirmed for all tested transformants by PCR using CPR-and CYP2D6 specific primers. All tested clones contained both genes ( fig. 2 ).
The microsomal expression of CYP2D6 and oxidoreductase as well as the activity of the enzymes was tested as described for the separate expression of both genes. Microsomes of clones expressing CYP2D6 only or negative controls did not show any product peak.
In oder to quantify the CYP expression, reduced CO-difference spectra, total protein concentrations and activities of the microsomal fractions from clones coexpressing CYP2D6 and CPR were measured. The CO difference spectrum in figure 8 clearly
shows a peak at 450 nm corresponding to the holo enzyme containing the heme group. As there is no peak at 420 nm all the CYP protein seems to be correctly 
Discussion
As already outlined in the introduction microsomal cytochromes P450 play a crucial role in the phase 1 reactions of the xenobiotic metabolism. Especially the human ones are needed by many pharmaceutical companies to test drug candidates for adverse drug interactions and thus are of high economic interest.
In this study we have shown the coexpression of functional human CYP2D6 and CPR in the methylotrophic yeast P. pastoris:
Strains coexpressing CPR and CYP2D6 each under control of the methanol inducible AOX1 promotor were generated by a strategy previously used for the coexpression of heavy and light chains of a Fab fragment. [32] Beside zeocin there is no other suitable antibiotic as selection marker for P. pastoris commonly in use. Only several auxotrophy markers are used, but due to their low efficiency the screening of a high number of colonies is generally required using them. This in turn is not suitable when screening for microsomal CYPs due to the elaborate preparation of microsomal fractions. Thus, a prerequisite was the generation of a co-expression vector containing both expression cassettes. All colonies screened after transformation with this coexpression vector integrated both expression cassettes into the genome as shown by PCR. Those strains expressing both, human CPR and CYP2D6 exhibited activity as shown by the conversion of different typical CYP2D6 substrates (dextrometorphan, 3-cyano-7-ethoxycoumarin) but also uncommon substrates such as parathion.
The presented assay based on the oxidation of parathion followed by the inhibition of the acetylcholine esterase provides a fast and easy to handle photometric assay for the detection of CYP activity. It does not require any pre-treatments such as extractions and there is no need for complicated and expensive devices such as HPLC, GC/MS, LC/MS. The substrate parathion is much cheaper than most of the fluorimetric substrates such as derivatives of coumarin. In addition to the detection of CYP activity the assay can be used for the monitoring of phosphorothionate pesticides as we recently have published elsewhere. [33] A comparison of the kinetic parameters of CYP2D6 from different recombinant expression systems (COS7, Baculovirus, E. coli, yeast) is provided in [20] Even a mixture of Pichia microsomes containing recombinant human oxidoreductase with microsomes containing recombinant human CYP2D6 did not result in any activity. However, probably this is due to a lack of fusion of the microsomes and might be overcome by improvement of the protocol.
Various soluble proteins have been expressed both secreted and not secreted in P. pastoris in the range of grams per litre. Although some CYPs from spiny lobster, spiny dogfish shark and cassava have been expressed in P. pastoris so far, [24] [25] [26] this is the first report of a mammalian, microsomal CYP expressed in a methylotrophic yeast. Additionally it is one of only few reports describing the coexpression of different proteins in one P. pastoris strain. [22, 32, 34] The chosen cloning strategy allows the generation of clones expressing additional by mixing the desired amounts of microsomes as described above.
In contrast to the mammalian or viral expression systems which are currently used in most cases for the production of recombinant mammalian CYPs (see relevant substrates using whole cells avoiding the isolation of microsomes which currently is the limiting step (will be published elsewhere). Currently this is done using recombinant E. coli, but as described above only with N-terminally modified CYPvariants. [11, 12] Thus, such biotransformations using Pichia strains coexpressing phase 
Experimental Section Chemicals
Unless stated otherwise all chemicals were purchased from Sigma-Aldrich Chemie (Steinheim, Germany), Fluka (Buchs, Germany), Merck (Darmstadt, Germany), Riedel de Haen (Seelze, Germany) at the highest purity available. 3-Cyano-7-ethoxycoumarin and 3-Cyano-7-hydroxycoumarin were obtained from Molecular Probes (Mo Bi Tec, Goettingen, Germany).
Oligonucleotides were purchased from Sigma ARK GmbH (Darmstadt, Germany). Acetylcholinesterase from Nippostrongilus brasiliensis expressed in P. pastoris was a gift from Dr. H. Schulze (ITB, Stuttgart, Germany).
Microorgansims, plasmids and growth conditions:
E. coli DH5α [F -endA1 hsdR17(rk - , mk + ) supE44 thi-1 λ -gyrA96 relA1 Δ(argF-
Recombinant DNA technologies
Standard DNA technologies were used unless stated otherwise. [35] The Genelute Plasmid Mini-Prep Kit (Sigma), the QIAPrep Midi Plasmid preparation kit (Qiagen, Hilden Germany), and the NucleoSpin Extract Kit (Machery & Nagel GmbH & Co KG, Düren, Germany) were used for plasmid DNA and DNA gel extractions, respectively.
Restriction enzymes and other DNA modifying enzymes were used as specified from the supplier (MBI Fermentas (St. Leon-Rot, Germany)). DNA-sequencing reactions were carried out on both strands of double-stranded templates using the BigDye
Terminator Cycle Sequencing Kit RR-100 (Applied Biosystems, Weiterstadt, Germany). The sequencing products were analysed on a ABI Prism™ 377 DNA Sequencer (Perkin Elmer, Shelton, USA). Standard protocols were used for the preparation and transformation of competent E. coli cells. [35] Transformation of P.
pastoris was done according to the Invitrogen electroporation method (Invitrogen).
The integration of the Pme I linearized vectors into the genome of P. pastoris clones was confirmed using gene specific primers and genomic DNA as template. Genomic DNA was prepared according to the Invitrogen manual (Invitrogen).
Construction of expression vectors
The genes encoding CYP2D6 and CPR were amplified by PCR from plasmids SK+2D6(374V) and hOR-PAK9, respectively, using two gene-specific primers for To combine both expression cassettes into a single vector, a strategy based on the specificity of the Bam HI and Bgl II restriction enzymes recognizing different sequences but producing compatible sticky ends was used: [12] The expression cassette of CYP2D6 in pPICZ-2D6 was isolated by double digestion
with Bam HI and Bgl II followed by gel extraction and ligated into pPICZ-CPRΔPme linearized either with Bam HI or Bgl II, respectively, resulting in the vector pPICZ-2D6-CPR.
Expression of recombinant proteins in P. pastoris
Recombinant clones selected on zeocin plates were picked and grown in 10 ml BMGY medium to an OD 600 of 5 -10. The cells of this preculture were then collected by centrifugation (5 min, 3000 g, room temperature) and used to inoculate BMMY medium (50 ml) in a baffled flask (500 ml) to an OD 600 ~ 1. Induction of the recombinant protein expression in the main culture was performed and maintained by daily addition of methanol (0.5 %). After 90 hours cells were harvested by centrifugation (3000 g, 10 min, 4°C).
Preparation of membrane fractions of P. pastoris
Cells were washed in homogenisation buffer (potassium phosphate (50 mM, pH 7.9); EDTA (1 mM); Glycerol (5 %); DTT (2 mM); PMSF (1 mM)) and resuspended to an OD 600 of 130. The cell suspension was mixed with an equal volume of acid washed glass beads (0.5-0.75 mm in diameter). Disruption and isolation of microsomes was done similar as previously described: [26] Cells were disrupted by vortexing (8x 30 s at 4°C with cooling on ice for 30 s between the cycles). The lysate was separated from cell debris and glass beads by centrifugation (12000 g, 10 min, 4°C). The supernatant was ultracentrifuged (100000 x g, 1 h, 4°C), the microsomal pellet was then resuspended in homogenisation buffer and stored at -80°C.
Quantification of cytochrome P450
Protein concentrations were determined using the BC Assay (Uptima interchim, Montluçon, France) according to the supplier's recommendation. BSA was used as standard.
CYP2D6 concentrations in the isolated membranes were determined by reduced carbon monoxide spectra as follows: [36] microsomes (100 µl, 15 -30 µg protein / µl) in sodium phospate buffer (0.1 M, pH 7.4) containing glycerol (10 %) and Triton X 100 (0.5 %) were incubated on ice for 10 min. Some sodium dithionite was added and insoluble particles were removed by centrifugation (3 min, 14000 rpm) using a microcentrifuge. The supernatant was transferred into UV-cuvettes and a reference spectrum was recorded from 400 to 500 nm (Ultrospec 3000 UV/Visible spectrophotometer, Pharmacia Biotech). The solution was then aerated with carbon monoxide for 30 s and afterwards the spectrum was measured again.
The Cytochrome P450 concentration was calculated with an extinction coefficient of
SDS-PAGE / Western Blotting
10 µl of the microsomal fraction were separated by SDS-Page using polyacrylamide gels (12.5 %) with a stacking gel (4 %) under reducing conditions. [37] Specific detection of the heterologous proteins was achieved by western blotting using CPRspecific and CYP2D6 specific antibodies purchased from BD Gentest (catalog 
CYP2D6 activity tests
Deethylation of 3-cyano-7-ethoxycoumarin
The deethylation of 3-cyano-7-ethoxycoumarin was measured according to Favreau with modifications: [38] substrate solution (100 µl, 3-cyano-7-ethoxycoumarin (100 µM) in potassium phosphate buffer (100 mM, pH 7.4), NADPH (3 mM), Pluronic F-68 (0.02%)) was pre-incubated in a microtiterplate well at 37°C for 5 minutes and mixed with microsomal protein (300 µg) in potassium phosphate buffer (100 mM, pH 7.4).
Samples were excited at 405 nm and emission at 460 nm was detected and recorded every 10 minutes for a total of 160 minutes using a FluoStar Fluorimeter (BMG Lab
Technologies, Offenburg, Germany).
Coupled acetylcholine esterase -CYP2D6 assay
The assay is based on the inhibition of the acetylcholine esterase by paraoxon, as described by Sams: [39] initially parathion is activated in a CYP2D6 catalyzed reaction to paraoxon. Therefore, a parathion solution (25 µl, 20 µg ml -1 in potassium phosphate buffer (50 mM, pH 7.5) were mixed with microsomal proteins (300 µg) and topped up to 75 µl with phosphate buffer. After 6 minutes of incubation, aqueous NADPH solution (25 µl, 5 mg ml -1 ) were added followed by 40 minutes incubation.
Potassium phosphate buffer (690 µl, 50 mM, pH 7.4), DNTB (100 µl, 7.8 mM in potassium phosphate buffer), and acetylcholine esterase solution (100 µl) were added to the inhibition mixture. After incubation for 30 minutes the enzyme reaction was started by addition of acetylthiocholine iodide (10 µl, 100 mM). Acetylcholine esterase activity was recorded and expressed as a percentage of the control activity measured without paraoxon (residual activity) as reported by Ellman. [40] The absorption at 412 nm was detected using a UV/Vis ultrospec 3000 photometer (Pharmacia Biotec, Freiburg, Germany). and glucose 6-phosphate dehydrogenase (4 U/ml)). The reaction was stopped by the addition of HCl (50 µl, 1 M).
Dextromethorphan O-demethylation analysis by HPLC and LC/MS
After addition of the internal standard d 3 -dextrorphan (100 pmol), the samples were mixed and centrifuged (16,000 g, 5 min). The supernatant was directly injected into the HPLC-system. The metabolite dextrorphan was separated and detected by HPLC-MS/MS spectrometry using a HPLC system (HP 1100, Agilent Technologies, Waldbronn, Germany) equipped with a Omnispher-C18 column (150x3 mm, 5 µM particle size, Varian, Darmstadt, Germany) and an ion trap mass spectrometer (HCT plus, Bruker Daltronics, Bremen, Germany). Elution was performed with a gradient of 15 % (1 % acetic acid/water) and 85 % (1 % acetic acid/acetonitrile ) to 50 %/50 % from 0 to 9.5 min. All incubations were performed in duplicate and in the linear range with respect to microsomal protein and incubation time. Control experiments were carried out in parallel using denaturated microsomes.
Data were processed using the software Quant Analysis (Bruker Daltronics). Enzyme kinetic data were analyzed using the program GraphPadPrism v3.0 (GraphPad Software Inc., San Diego, CA). Details will be published elsewhere.
Reductase Activity
The reductase catalysed reduction of bovine heart cytochrome c at 550 nm was measured essentially as described: [41] cytochrome c solution (100 µl, 6.5 mg/ml in potassium phosphate buffer (50 mM, pH 7.5)) were mixed with microsomal protein (120 µg) and topped up with potassium phosphate buffer to 950 µl. Reactions were started by adding aqueous NADPH solution (50 µl, 9 mg ml -1 ). Activities were measured using a UV/Vis ultrospec 3000 photometer (Pharmacia Biotec, Freiburg, Germany) and calculated using an extinction coefficient of 21 mM -1 cm -1 . Kinetic data were analysed using the swift program (Pharmacia). One unit is defined as µmol min PCR using genomic DNA of clones C1-C4 with primers specific for CPR. 
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